BioCentury
ARTICLE | Finance

Xanthopoulos' passion play

Why Kleanthis Xanthopoulos left Regulus to join Vendel Group

June 8, 2015 7:00 AM UTC

With his role of running Regulus Therapeutics Inc. (NASDAQ:RGLS) in the rearview mirror, Kleanthis Xanthopoulos expects his new job at Vendel Group will be a smaller-scale, California version of what Third Rock Ventures does - creating and running portfolio companies in their initial stages.

Vendel Group is a family office with an undisclosed sum under management. ...